Rates of Myocardial Infarction and Coronary Artery Disease and Risk Factors in Patients Treated With Radiation Therapy for Early-Stage Breast Cancer
| dc.contributor.author | Ural, Ali Uğur | |
| dc.contributor.author | Avcu, Ferit | |
| dc.contributor.author | Baran, Yusuf | |
| dc.coverage.doi | 10.1002/cncr.22804 | |
| dc.date.accessioned | 2016-08-12T08:35:54Z | |
| dc.date.available | 2016-08-12T08:35:54Z | |
| dc.date.issued | 2007 | |
| dc.description | Correspondence | en_US |
| dc.description.abstract | We read the interesting article by Jagsi et al on the increased rates of coronary artery disease in patients treated with radiation therapy for early-stage breast cancer.1 In their study, those authors concluded that the findings support further assessment of clinical outcomes when newer techniques of chemotherapy planning are employed as well as investigation of the potential role of innovative techniques. However, there was no mention of the novel radiosensitizing and chemosensitizing effects of bisphosphonates (BPs), which inhibit tumor cell adhesion to bone, and tumor growth in breast cancer. | en_US |
| dc.identifier.citation | Ural, A. U., Avcu, F., and Baran, Y. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 110(2), 469-470. doi:10.1002/cncr.22804 | en_US |
| dc.identifier.doi | 10.1002/cncr.22804 | en_US |
| dc.identifier.doi | 10.1002/cncr.22804 | |
| dc.identifier.issn | 0008-543X | |
| dc.identifier.issn | 1097-0142 | |
| dc.identifier.scopus | 2-s2.0-34547148070 | |
| dc.identifier.uri | http://doi.org/10.1002/cncr.22804 | |
| dc.identifier.uri | https://hdl.handle.net/11147/2092 | |
| dc.language.iso | en | en_US |
| dc.publisher | John Wiley and Sons Inc. | en_US |
| dc.relation.ispartof | Cancer | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Bisphosphonic acid derivative | en_US |
| dc.subject | Radiosensitizing agent | en_US |
| dc.subject | Zoledronic acid | en_US |
| dc.subject | Breast cancer | en_US |
| dc.subject | Cancer inhibition | en_US |
| dc.title | Rates of Myocardial Infarction and Coronary Artery Disease and Risk Factors in Patients Treated With Radiation Therapy for Early-Stage Breast Cancer | en_US |
| dc.type | Letter | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | 0000-0002-1056-4673 | |
| gdc.author.id | 0000-0002-1056-4673 | en_US |
| gdc.author.institutional | Baran, Yusuf | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::letter | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
| gdc.description.endpage | 470 | en_US |
| gdc.description.issue | 2 | en_US |
| gdc.description.publicationcategory | Diğer | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | 469 | en_US |
| gdc.description.volume | 110 | en_US |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W4235108014 | |
| gdc.identifier.pmid | 17559123 | |
| gdc.identifier.wos | WOS:000247985600032 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 1.0 | |
| gdc.oaire.influence | 2.846753E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.keywords | Mice, Inbred BALB C | |
| gdc.oaire.keywords | Bone Density Conservation Agents | |
| gdc.oaire.keywords | Diphosphonates | |
| gdc.oaire.keywords | Imidazoles | |
| gdc.oaire.keywords | Myocardial Infarction | |
| gdc.oaire.keywords | Breast Neoplasms | |
| gdc.oaire.keywords | Coronary Artery Disease | |
| gdc.oaire.keywords | Zoledronic Acid | |
| gdc.oaire.keywords | Mice | |
| gdc.oaire.keywords | Risk Factors | |
| gdc.oaire.keywords | Animals | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.popularity | 7.8277446E-10 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.13835978 | |
| gdc.openalex.normalizedpercentile | 0.64 | |
| gdc.opencitations.count | 5 | |
| gdc.plumx.crossrefcites | 3 | |
| gdc.plumx.mendeley | 8 | |
| gdc.plumx.pubmedcites | 2 | |
| gdc.plumx.scopuscites | 3 | |
| gdc.scopus.citedcount | 3 | |
| gdc.wos.citedcount | 2 | |
| relation.isAuthorOfPublication.latestForDiscovery | 7bb863bb-9384-4a07-9fbb-b9c1ab7634a3 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4013-8abe-a4dfe192da5e |